Investor Relations

Stock price graph
     
DDXS [OT] : $0.84  + 0.04
Last Updated: 3:52 PM ET on Apr 15, 2014

diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.

The PLAC Test for Lp-PLA2, diaDexus' flagship product, addresses key unmet medical need, providing actionable information. The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

diaDexus Corporate Fact Sheet - March 2014 PDF

PLAC Test Fact Sheet - January 2014 PDF

Lp-PLA2 Fact Sheet - January 2014 PDF

Heart Failure Fact Sheet - March 2014 PDF

View all »   RSSRecent Releases

Mar 5, 2014
diaDexus, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results

Mar 5, 2014
diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific to Advance Risk Prediction in Heart Failure



 

©2014 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.